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Bisphenol A (BPA) is a high-volume indus-
trial chemical that is polymerized to form 
polycarbonate plastics and epoxy resins, and 
is a constituent of some polyvinyl chloride 
(PVC) plastics. These materials are used 
to line metal food and drink containers, as 
dental sealants, and for manufacturing poly-
carbonate drink containers. The ester bonds 
that enable the polymerization of BPA can be 
broken, particularly under exposure to heat, 
releasing free BPA (Kang et al. 2006).
BPA has long been described as a weak 
estrogen due to its low affinity for nuclear estro-
gen receptors, but recent studies have shown 
that BPA is equipotent with estradiol in its abil-
ity to initiate rapid nongenomic responses from 
membrane surface receptors (Quesada et al. 
2002; Wozniak et al. 2005). Whether BPA can 
cause human health effects is a matter of some 
debate; the potential for harm to infants and 
the fetus is currently considered more likely 
than harm to adults [National Toxicology 
Program (NTP) 2008; vom Saal et al. 2007].
The Centers for Disease Control and 
Prevention (CDC) estimates that 93% of 
Americans ≥ 6 years of age have detectable 
urine levels of BPA (parent BPA and con-
jugated metabolites), based on 2003–2004 
data from the National Health and Nutrition 
Examination Survey (NHANES) (Calafat 
et al. 2008b). The median BPA for all ages 
was 2.7 ng/mL, with the lowest creatinine-
corrected levels found in males, Mexican 
Americans, and subjects with higher income.
Exposure is thought to be almost exclu-
sively from food (NTP 2008). For example, 
Wilson et al. (2007) examined exposure to 
BPA and other phenols in 275 young chil-
dren 1.5–5 years of age. They concluded that 
99% of BPA exposure was dietary based on 
measurements of BPA levels from a variety 
of sources such as food, air, and house dust. 
Because their preliminary survey did not find 
BPA in tap water, it was not subsequently 
measured in the main study (Wilson N, per-
sonal communication). Miyamoto and Kotake 
(2006) modeled Japanese exposures and con-
cluded that 95% of adult male BPA intake 
was from food and drink, excluding water.
In human adults, BPA is generally described 
as rapidly metabolized, with elimination thought 
to be virtually complete within 24 hr of expo-
sure. This conclusion is based primarily on three 
human experimental studies of acute exposures, 
although animal studies have generally led to 
similar conclusions (Vandenberg et al. 2007).
Human pharmacokinetics after single 
exposures were first reported by Völkel and 
colleagues (2002). In this study, they gave six 
volunteers deuterium-labeled BPA (5 mg) 
by mouth and followed elimination in both 
blood and urine for 42 hr. Urine levels, mea-
sured every 6 hr, peaked 6 hr after administra-
tion (19.1 µmol; 4,360 ng/mL); the authors 
reported a urinary elimination half-life of 
5.4 hr. Teeguarden et al. (2005) later used these 
data in the construction of a physiologically 
based pharmacokinetic model.
In their second acute exposure study, 
Völkel et al. (2005) gave a much smaller dose 
of labeled BPA (25 µg) to six volunteers, and 
followed blood and urine levels for 7 hr. Urine 
BPA peaked at 1–3 hr (42 nmol; 9.6 ng/mL), 
with a reported urinary elimination half-life 
of 4 hr. 
Tsukioka et al. (2004) gave 100 µg oral 
deuterium-labeled BPA to one subject and 
measured urine BPA levels for 26.5 hr. Urine 
BPA peaked at 30 min (90 ng/mL) and 
returned to near baseline (2.2 ng/mL) in this 
subject by 5 hr. They subsequently dosed 25 
subjects with 50 µg BPA, and found that, on 
average, 76% of administered BPA was elimi-
nated in the urine within 5 hr.
If the rapid BPA clearance seen in these 
acute exposure studies also occurs in the 
chronic exposures experienced by the general 
population, and if BPA exposure is almost 
entirely through non-water dietary intake, 
then BPA levels in the population should be 
inversely related to fasting time. Fasting time, 
in this context, is analogous to the time after 
dosing in an experimental pharmacokinetic 
study. At the start of fasting, BPA exposure 
should essentially stop and BPA elimination 
should follow rapidly. Therefore, participants 
with long fasting times before urine collection 
should have substantially lower BPA urine 
levels than those with shorter fasting times. 
In this exploratory study, we present evi-
dence that these NHANES BPA data are not 
consistent with the current consensus that 
BPA exposures are both rapidly cleared and 
almost entirely related to food intake. Instead, 
it appears plausible that there is substantial 
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Ba c k g r o u n d: It is commonly stated in the literature on human exposure to bisphenol A (BPA) that 
food is the predominant BPA exposure source, and that BPA is rapidly and completely cleared from the 
body. If this is correct, BPA levels in fasting individuals should decrease with increased fasting time.
oBjectives: We set out to investigate the relationship between urine BPA concentration and fast-
ing time in a population-based sample.
Me t h o d s : We modeled log BPA urine concentration as a function of fasting time, adjusted for 
urine creatinine and other confounders, in 1,469 adult participants in the 2003–2004 National 
Health and Nutrition Examination Survey. We estimated the BPA “population-based half-life” 
(pop½) for a fasting time of 0–24 hr, < 4.5 hr, 4.5–8.5 hr, and > 8.5 hr. 
re s u l t s: The overall pop½ for the 0- to 24-hr interval was 43 hr [95% confidence interval (CI), 
26–119 hr]. Among those reporting fasting times of 4.5–8.5 hr (n = 441), BPA declined significantly 
with fasting time, with a pop½ of 4.1 hr (95% CI, 2.6–10.6 hr). However, within the fasting time 
intervals of 0–4.5 hr (n = 129) and 8.5–24 hr (n = 899), we saw no appreciable decline. Fasting time 
did not significantly predict highest (> 12 ng/mL) or lowest (below limit of detection) BPA levels. 
co n c l u s i o n s: Overall, BPA levels did not decline rapidly with fasting time in this sample. This 
suggests substantial non  food exposure, accumulation in body tissues such as fat, or both. Explaining 
these findings may require experimental pharmacokinetic studies of chronic BPA exposure, further 
examination of BPA levels and effects in fat, and a search for important non  food sources.
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non  food exposure, accumulation in body com-
partments with long elimination times, or both. 
Methods
Study population. We used data from the 
2003–2004 NHANES for this analysis. 
NHANES, conducted by the CDC National 
Center for Health Statistics (Hyattsville, MD), 
is a multistage, stratified, clustered sample of the 
civilian, noninstitutionalized U.S. population. 
Data are acquired through standardized 
examinations at mobile examination centers 
throughout the United States, with 30 counties, 
or groups of contiguous counties, surveyed 
during each 2-year period. Certain subgroups 
are sampled at a higher rate than other 
demographic groups, including older adults, 
Mexican Americans, non-Hispanic blacks, 
and low-income persons. A CDC institutional 
review board approved the study protocol, and 
informed written consent was obtained from all 
subjects. Detailed methods have been published 
elsewhere (CDC 2008). 
In NHANES 2003–2004, a random one-
third subsample of participants ≥ 6 years of 
age (n = 2,567) was selected for urinary BPA 
measurements. We excluded ages < 18 (34%) 
because mean fasting times were substantially 
shorter than those of adults, and because 
adjustment for body mass index (BMI) is com- com-
plex in children and adolescents. We excluded 
those ≥ 85 years of age (2%) to reduce pharma- pharma-
cokinetic variability and effects of comorbidity. 
We also excluded participants who reported 
fasting times > 24 hr (1%) to reduce regression 
leverage of these fasting time outliers. This left 
1,469 participants with complete data for the 
measures described below.
Fasting time. Except for insulin-dependent 
diabetics, all adults were asked to fast, although 
failing to fast adequately (refusal or mistake) 
did not disqualify participants. Appointment 
slips, given to subjects in advance, indicated 
that once fasting started, subjects should: 
a) “not eat or drink anything except water” 
and b) have “no coffee, tea, food, dietary sup-
plements, mints, cough drops, gum, snacks, or 
beverages, and no nicotine for at least 3 hours” 
(CDC 2004b). Participants who attended the 
morning session were asked to fast 9.5 hr (over-
night). Afternoon and evening session subjects 
were asked to fast 6 hr (CDC 2004a).
At each mobile examination center, phle-
botomists assessed subject fasting compliance. 
Fasting time was calculated by CDC (in hours 
and minutes) using the participant’s response 
at the time of blood and urine collection to 
the question “When was the last time you ate 
or drank anything other than plain water?” 
(CDC 2006). 
However, phlebotomists were also instructed 
to consider consumption of “diet soda, black 
coffee or tea with saccharine or Equal” as 
equivalent to plain water, and thus these items 
were permitted during “fasting.” Subjects were 
also asked whether, since fasting began, they 
had consumed coffee/tea with cream/sugar, 
alcohol, gum, mints, lozenges, cough drops, 
antacids, laxatives, antidiarrheals, or dietary 
supplements. Consumption of these items was 
recorded, but without modifying the overall 
fasting time (CDC 2004b).
BPA measurement. One spot urine sample 
was collected from each participant and ana-
lyzed by CDC using HPLC and tandem mass 
spectroscopy to determine BPA concentration 
(sum of BPA parent compound plus conju-
gated metabolites; nanograms per milliliter). 
Samples below the limit of detection (LOD; 
0.4 ng/mL) were coded as LOD divided by the 
square root of 2 (Calafat et al. 2008b).
Detailed BPA analysis methods have been 
published, including the quality control sys-
tem that was used to prevent contamination 
during collection, handling, and analysis of 
samples (CDC 2007b). 
We log-transformed BPA in regres-
sion analyses to normalize its distribution. 
Differences in urine dilution were corrected 
using urine creatinine. In regressions, this cor-
rection was performed by adding to the model 
the function of urine creatinine that provided 
the best model fit (urine creatinine and creati-
nine square root). For descriptive statistics, cre-
atinine-corrected BPA was calculated as BPA 
divided by urine creatinine. 
BPA levels by fasting hour. To estimate the 
hour-by-hour trajectory of BPA in the popula-
tion, we fit linear regression models in which 
fasting time was represented by 23 dummy vari-
ables, each representing a 1-hr interval from 1 
to 24 hr with 0–1 hr as the reference group. To 
plot these results, we used the regression model 
to predict BPA by hour for a “standard person” 
having the median of continuous variables and 
mode of categorical variables. Because creati-
nine correction in our regressions was achieved 
by including urine creatinine as a covariate, 
the model predicts BPA rather than creatinine-
corrected BPA. Hence predicted BPA results 
are given in nanograms per milli  liter rather than 
micrograms per gram creatinine. 
BPA population-based half-lives. Plots of 
log concentration versus time are commonly 
used to assess toxicant elimination in experi-
mental pharmacokinetic studies. Under first-
order kinetics, in which elimination rate is 
proportional to internal concentration, the plot 
of log concentration vs. time is a straight line 
unless the toxicant distributes from a central 
compartment (e.g., blood) to a peripheral com-
partment with a slower elimination rate (e.g., 
fat). The elimination half-life is computed as 
–ln(2) divided by the slope (Shen 2007). 
In our study, we adapted this approach to 
a food-based population exposure by regressing 
log BPA concentration against fasting time, in 
which each data point represents an individual 
participant. As in experimental kinetics, we 
calculated the half-life as –ln(2)/slope, except 
that in our population-based approach, the 
slope was represented by the fasting time coeffi-
cient from adjusted linear regressions described 
below. We computed the 95% confidence 
interval (CI) of the half-life from the lower and 
upper bounds of the regression coefficient CI 
in similar fashion (Bryan et al. 1990).
Because we are using pharmacokinetic con-
cepts in a nonstandard epidemiologic manner, 
we wish to carefully distinguish between experi-
mentally determined kinetics and population-
based observations from which kinetics must be 
inferred. To this end, we use the term “half-life” 
in its conventional pharmacokinetic sense and 
the term “population-based half-life” (pop½) for 
derived kinetics seen in these population data. 
In addition to examining the slope over 
the entire fasting interval (0–24 hr), we also 
subdivided this time period into three sub-
intervals. We selected cut points that would 
maximize the slope of the regression line (e.g., 
result in the shortest pop½) during the period 
when rapid excretion should be occurring. This 
was done by fitting regressions to explore a 
range of intervals from fasting time > 2–5 hr 
to < 6–10 hr, in half-hour increments (e.g.,   
2.5–8.5 hr, 3–8.5 hr, 4.5–9 hr, 4.5–9.5 hr). 
The sharpest slope was found from 4.5–8.5 
hr. We therefore defined the fasting hour 
ranges used in our analyses as 0–4.5 (n = 129),   
4.5–8.5 (n = 441), and 8.5–24 hr (n = 899). 
Sensitivity analysis. Fasting time is an 
important variable in this analysis, but is self-
reported. Intentional exaggeration of fasting 
time could be a problem because subjects were 
given incentives of $100 for adequate fasting 
and $70 otherwise. We used serum glucose as 
a means of identifying subjects at greatest risk 
of fasting time exaggeration, and repeated our 
pop½ analyses with these subjects excluded. 
In subjects with normal glucose tolerance, 
serum glucose should return to normal fasting 
level (< 100 mg/dl) within 4–6 hours of eating 
(Galgani et al. 2006), so we classified subjects 
as at risk of exaggerated fasting time if they 
reported fasting ≥ 4.5 hours and had a serum 
glucose ≥ 100. 
Because certain non-water dietary intake 
was permitted after the start of fasting, we also 
repeated pop½ analyses after identifying and 
excluding subjects at risk of important “other-
than-water” consumption. We excluded sub-
jects who either a) reported consuming, after 
fasting began, coffee/tea with cream/sugar, 
alcohol, gum, mints, lozenges, cough drops, 
antacids, laxatives, antidiarrheals, or dietary 
supplements, or b) were most likely to have 
consumed “diet soda, black coffee or tea with 
saccharine or Equal.” Group 1 was specifi-
cally recorded in the phlebotomy data and 
easily excluded. Group 2, however, was not 
recorded; therefore we used the 24-hr dietary Stahlhut et al.
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history to identify and exclude subjects who 
consumed diet soda, coffee, or tea on the pre-
vious day (with or without sweeteners). 
Statistical analysis. We performed mul-
tiple linear regression analyses, adjusted for 
fasting time, urine creatinine, sex, age, race, 
BMI, income, and examination session. Age 
was computed as age in months divided by 12. 
Race was categorized as Mexican American, 
white, black, and other/mixed. Income was 
represented by the poverty income ratio, the 
ratio of family income to the poverty line, 
adjusted for family size (continuous, minimum 
= 0; top-coded at 5). The examination session 
attended was coded as morning, afternoon, or 
evening, with the exact time of visit omitted 
by CDC to help ensure privacy. We also used 
logistic regression, with covariates as above, 
to identify predictors of low BPA levels (BPA 
< LOD; n = 114) as well as the highest BPA 
levels (BPA > 12 ng/mL; n = 115).
To assess the effects of hepatic and 
renal function, we also repeated these 
analyses, adding to the model the liver 
enzyme γ-glutamyl transferase, and glomeru-
lar filtration rate, a measure of renal func-
tion. We estimated the glomerular filtration 
rate using the four-variable equation from the 
Modification of Diet in Renal Disease study 
(Levey et al. 1999).
In complex surveys such as NHANES, sur-
vey design variables are available to enable an 
analyst to make estimates consistent with those 
that would result from a random sample of the 
U.S. population (Lee and Forthofer 2005). 
Sample weights adjust for oversampling and 
survey imperfections such as nonresponse bias. 
Survey cluster variables are used to account for 
the multilevel sampling strategy, in which, for 
instance, people from a given neighborhood 
or county are expected to be more similar to 
each other than to people from other parts of 
the country.
In this study, we have omitted survey 
design variables from our analyses because this 
approach is most favorable to the standard view 
of BPA as a rapidly cleared exposure. Survey 
variables generally have the effect of increasing 
standard errors and reducing power—in this 
case, reduced power to detect a slope of BPA 
concentration versus time that should be decid-
edly different from zero if the standard view is 
correct. By choosing not to use the weights and 
other design adjustments, we retain the sta-
tistical power found in a convenience sample 
analysis, but lose the ability to generalize to the 
U.S. population as a whole. Survey statisticians 
have extensively debated under what condi-
tions survey design variables are required in 
regression analyses (Lee and Forthofer 2005).
R (version 2.7.0) was the principal statisti-
cal system used in this study (R Development 
Core Team 2008). Regression diagnostics were 
performed with the “car” and “alr3” packages; 
graphics were created using “ggplot2” (Fox 
2008; Weisberg 2008; Wickham 2008). A 
second analyst replicated key statistics inde-
pendently using SAS 9.1 (SAS Institute Inc., 
Cary, NC).
Results 
Table 1 shows participant demographics by 
fasting time interval for the 1,469 subjects. Of 
these, 48 subjects (3.3%) reported consuming, 
after fasting began, coffee/tea with cream/sugar, 
alcohol, gum, mints, lozenges, cough drops, 
antacids, laxatives, antidiarrheals, or dietary 
supplements. The 24-hr dietary history identi-
fied 119 subjects (8.1%) who consumed diet 
soft drinks the previous day, and 836 (56.9%) 
who consumed coffee or tea. Together, there 
were 920 (62.6%) potential “other-than-water” 
dietary consumers during fasting.
Table 1. Demographic frequencies [no. (%)] and medians,a by fasting time interval.
  Fasting time interval
Characteristic  0–24 hr  0–4.5 hr  4.5–8.5 hr  8.5–24 hr
Male  710 (48)  64 (50)  222 (50)  424 (47)
Female  759 (52)  65 (50)  220 (50)  474 (53)
Mexican American  314 (21)  31 (24)  88 (20)  195 (22)
White  749 (51)  52 (40)  242 (55)  455 (51)
Black  288 (20)  37 (29)  66 (15)  185 (21)
Other/mixed  118 (8)  9 (7)  46 (10)  63 (7)
Age (years)  44.2  41.3  47.9  43.5
Poverty income ratio  2.1  1.5  2.2  2.1
BMI  27.1  26.6  26.8  27.3
Fasting time (hr)  10.9  2.3  6.9  13.1
aThese descriptive statistics are unweighted and thus describe this sample, not the U.S. population generally. 
Table 2. Urinary BPA concentrations (no. of subjects, median, µg/g creatinine).
  By fasting time  By session   
  0–24 hr  0–4.5 hr  4.5–8.5 hr  8.5–24 hr  Morning  Afternoon  Evening
  No.  Median  No.  Median  No.  Median  No.  Median  No.  Median  No.  Median  No.  Median
All  1,469  2.3  129  2.6  441  2.3  899  2.4  697  2.4  547  2.2  225  2.4
Sex
  Male  710  2.1  64  2.4  222  2.0  424  2.1  325  2.2  265  2.0  120  2.3
  Female  759  2.5  65  2.7  219  2.4  475  2.6  372  2.5  282  2.5  105  2.7
Age (years)
  18–40  630  2.4  61  2.8  168  2.3  401  2.5  294  2.5  218  2.3  118  2.4
  40–60  402  2.4  34  2.4  122  2.3  246  2.3  182  2.6  153  2.3  67  2.5
  60–85  437  2.0  34  2.4  151  1.9  252  2.1  221  2.1  176  1.9  40  2.3
Race
  Mexican American  314  2.0  31  2.3  88  1.8  195  2.0  142  2.0  127  2.0  45  1.9
  White  749  2.4  52  2.7  242  2.3  455  2.5  369  2.5  271  2.2  109  2.7
  Black  288  2.6  37  2.9  66  2.5  185  2.7  135  2.8  105  2.6  48  2.4
Poverty income ratio
  0–1.99  703  2.5  75  2.5  197  2.5  431  2.5  324  2.5  276  2.3  103  3.0
  2–4.99  532  2.3  38  2.7  175  2.1  319  2.3  250  2.4  204  2.1  78  2.4
  5   234  2.1  16  2.7  69  1.8  149  2.2  123  2.2  67  2.1  44  1.9
BMI
  16–25  515  2.4  53  2.5  161  2.3  301  2.3  237  2.4  188  2.2  90  2.4
  25–30  470  2.3  26  2.9  138  2.0  306  2.3  228  2.5  183  2.0  59  2.3
  30–65  484  2.4  50  2.4  142  2.3  292  2.4  232  2.3  176  2.3  76  2.7
Session
  Morning  697  2.4  43  3.0  7  2.0  647  2.4           
  Afternoon  547  2.2  58  2.4  285  2.1  204  2.2           
  Evening  225  2.4  28  2.4  149  2.4  48  2.4           
These descriptive statistics are unweighted and thus describe this sample, not the U.S. population generally.BPA population-based half-life in NHANES
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Unadjusted BPA levels vary minimally 
by fasting time. Table 2 shows unweighted 
median urinary BPA concentrations, by sub-
group, corrected for (i.e., divided by) urine 
crea  tinine. Overall, a small decline is seen 
between 0–4.5 hr and the later fasting time 
periods (analysis of variance on log-transformed 
means; p = 0.046). Figure 1 is a scatterplot of 
BPA versus fasting time. Wide scatter is evident 
without clear trends. The creatinine-corrected 
scatterplot is similar (not shown).
BPA kinetics suggested by adjusted models. 
Figure 2 shows BPA (ln) versus fasting hour, 
as determined by adjusted linear regression. 
Individual points were predicted from the 
regression model using a “standard person” 
having the median of continuous variables and 
mode of categorical variables—which for these 
data was a 44-year-old white female from the 
morning session with poverty income ratio = 2.1, 
BMI = 27, and urine creatinine = 122 mg/dL. 
Table 3 shows the results of the pop½ 
regressions, accompanied by an example 
calculation. The pop½ over the 0–24 hr 
interval was 43 hr (95% CI, 26 to 119, p = 
0.002). When regressions were stratified by 
fasting time intervals, substantial differences 
in pop½ were seen. For individuals who fasted 
0–4.5 hr, the slope was essentially zero, yielding 
a pop½ of 418 hr (95% CI, 4.7 to –4.8 hr, 
p = 0.98). A nonsignificant trend was also seen 
in the interval from 8.5 to 24 hours (pop½ 
= 38 hr; 95% CI, 17 to –225 hr; p = 0.09). 
However, for those fasting 4.5–8.5 hr there was 
a sharp decline in BPA concentration over the 
period (pop½ = 4.1 hr; 95% CI, 2.6 to 10.6 hr; 
p = 0.001). Adding gamma-glutamyl transferase 
and glomerular filtration rate to these models 
had minimal, nonsignificant effects (results not 
shown). As shown in Table 3, results did not 
change substantially after excluding fasting sub-
jects with higher than expected serum glucose, 
or subjects at risk of “other-than-water” dietary 
consumption during fasting.
When predictions for the “standard per-
son” were made from a regression over the 
interval from 4.5 hr (peak) to 24 hr, the BPA 
level at 4.5 hr was 4.04 ng/mL and at 24 hr 
was 3.05 ng/mL—a decline of 25% over 
19.5 hr. When predictions were made using 
the peak and trough values taken from Figure 
2, the levels declined 46% over 17 hr—from 
the peak of 4.59 ng/mL at 4–5 hr (n = 21) to 
a trough of 2.48 ng/mL at 21–22 hr (n = 19). 
BPA extremes not predicted by fasting 
time. “BPA < limit of detection” was not 
predicted by fasting time [odds ratio (OR) 
= 1.03; 95% CI, 0.98 to 1.09; p = 0.28]. 
Significant predictors were increasing age 
(continuous years; OR = 1.02; 95% CI, 1.01 
to 1.03; p = 0.003), race, and urine creatinine. 
Whites were less likely to be below the LOD 
than Mexican Americans (OR = 0.38; 95% 
CI, 0.21–0.69; p = 0.001). 
“BPA > 12 ng/mL” was not predicted by 
fasting time (OR = 0.97; 95% CI, 0.93 to 
1.01; p = 0.15). Significant predictors were 
female sex (OR = 1.8; 95% CI, 1.2 to 2.8; 
p = 0.005), income (higher income less likely; 
OR = 0.86; 95% CI, 0.75 to 0.99; p = 0.03), 
and urine creatinine. When only considering 
long fasting subjects (8.5–24 hr), and excluding 
at risk subjects as previously described, 7.5% of 
participants had a BPA level > 12 ng/mL, with 
a maximum of 80.1 ng/mL.
Discussion
In these NHANES data, the population-
based half-life is much longer than expected 
based on published acute exposure studies. 
Regressions demonstrate a strong BPA decline 
in the 4.5–8.5 hr interval, possibly represent-
ing an initial elimination phase subsequent to 
oral intake. However, from 8.5 to 24 hr, the 
slope is essentially flat, so pop½ is very long.
The relationship between fasting time 
and the highest BPA levels (12–80 ng/mL) 
was weak, and high levels were seen in some 
long-fasting subjects. Even when restricted to 
participants fasting 8.5–24 hr, and excluding 
at risk subjects as previously described, 7.5% 
of participants had a BPA level > 12 ng/mL. 
These results are substantially greater than the 
national median (2.7 ng/mL) determined by 
Calafat et al. (2008b), and suggest the possi-
bility of important non  food exposure.
Figure 1. Unadjusted urine BPA level versus fasting time. BPA is not creatinine-corrected; 
fasting time is self-reported. Points at 0.3 ng/mL BPA are < LOD (see "Methods"). 
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Figure 2. Adjusted urine BPA level versus fasting time. 
This plot shows BPA levels (± SE) by fasting time hour 
as determined by linear regression, adjusted for sex, 
age, race, poverty income ratio, BMI, session, and 
urine creatinine. Specific BPA levels are computed 
from the regression based on a “standard” person 
(see “Results“). SEs appear symmetrical because of 
the log scale. The size (area) of each point is propor-
tional to the square root of the unweighted n (number 
of observations) in that fasting hour interval.
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Non  food exposures have been described. 
Yamamoto et al. (2000), for example, found 
substantial migration of BPA from PVC hoses 
into room temperature water. BPA migration 
produced substantial BPA levels within 24 hr 
(median 329 ng/mL). Because PVC pipe is 
approved for use in residential water supply 
lines in many cities, BPA exposure from this 
source (by ingestion or inhalation) deserves 
investigation. A sizable fraction of this BPA 
would be chlorinated, however (Yamamoto and 
Yasuhara 2002). Chlorinated BPA species were 
not measured in NHANES 2003–2004 (CDC 
2007a) or in the children´s study by Wilson 
et al. (Wilson N, personal   communication). 
BPA has also been measured in recycled 
and carbonless copy paper (Ozaki et al. 2004). 
Reviews by Kang et al. (2006) and Vandenberg 
et al. (2007) describe other potential sources, 
such as dental sealants, dust, air, sewage 
effluents, and landfill leachates. 
Although acute, single-dose human 
experiments give compelling evidence that most 
BPA is rapidly excreted, frequent exposures 
could result in accumulation if BPA distributes 
to tissues that release BPA slowly. The log of the 
BPA octanol–water partition coefficient (Kow) 
has been estimated at 2.2–3.82 (NTP 2008). 
Thus BPA is lipophilic and could potentially 
accumulate in fat or other lipid-rich tissues.
BPA levels in fat have been reported. In 
chronically exposed rodents, Nunez and col-
leagues (2001) found BPA levels 8–10 times 
higher in brown fat than in serum. In women, 
Fernandez et al. (2007) measured BPA in adi-
pose tissue and found, for all subjects, a mean 
of 3.2 ng BPA/g fat and 8.2 ng chlorinated 
BPA/g fat. Olea et al. (2008) found substan-
tially greater levels in children. Their mean levels 
for all subjects were 10.7 ng BPA/g fat and 19.4 
chlorinated BPA ng/g fat (Olea N, personal 
communication). The BPA concentrations 
from these human studies are much greater 
than those recently shown to reduce the pro-
duction of adiponectin in human adipose tissue 
explants (Hugo et al. 2008). Low adiponectin 
has been correlated with insulin resistance and 
vascular inflammatory states (Hajer et al. 2008), 
whereas total urine BPA (BPA and conjugated 
metabolites) has been correlated with cardio-
vascular disease and diabetes (Lang et al. 2008). 
Thus BPA accumulation in fat, if common, 
could have important health implications.
Our analysis has several limitations: exclu-
sion of children and the very elderly, self-
reported fasting time, non-use of complex 
survey variables, and the question of BPA 
contamination or measurement error.
Because we limited our examination to adults 
18–85 years of age, these results do not necessar-
ily apply to children or to those > 85 years of 
age. Although neonates have some capacity to 
metabolize BPA (Calafat et al. 2008a), neonates 
and young infants have immature glucuronida-
tion capacity generally (Alcorn and McNamara 
2003), which is the primary means by which 
humans metabolize BPA. In the elderly, changes 
in body composition and a decline in renal 
function may affect volume of distribution and 
excretion rates (Turnheim 2003).
The accuracy of self-reported fasting time 
appears acceptable. Results did not change 
substantially after excluding fasting subjects 
with higher than expected serum glucose (i.e., 
risk of fasting time exaggeration), or those at 
risk of “other-than-water” dietary BPA expo-
sure during fasting. Although subjects who 
reported adequate fasting were compensated 
$30 more than those who did not, “adequate” 
fasting was defined as 9.5 hr for the morning 
examination session and 6 hr for the afternoon 
and evening sessions. Because longer fasting 
times than these provided no additional com-
pensation, we do not believe intentional exag-
geration is a satisfactory explanation of our 
results beyond these fasting time minimums.
Because we did not use complex sur-
vey variables in our primary analyses, these 
results cannot be precisely generalized to the 
entire U.S. population. However, because we 
adjusted for the demographic covariates related 
to oversampling, the complex survey analy-
sis method proposed by Korn and Graubard 
(1991) would produce regression coefficients 
(and thus population-based half-lives) very sim-
ilar to ours. The difference is that their method, 
like other such survey methods, increases the 
standard errors and would make it more dif-
ficult to detect a BPA decline with slope dif-
ferent from zero. Our smaller standard errors 
are thus more similar to those found in typical 
cross-sectional studies, except that NHANES 
Table 3. Pop½ regression results, sensitivity analyses, medians (µg/g creatinine), and example calculation.a
Fasting time  All  Other-than-water consumption exclusionb  High-glucose exclusionc  Both exclusions
0–24 hr            
No.  1,469  549  1,148  465
Median  2.3  2.3  2.3  2.3
Fasting time betad (95% CI)  –0.0162 (–0.0267 to –0.0058)  –0.0166 (–0.0311 to –0.002)  –0.0182 (–0.0292 to –0.0072)  –0.0176 (–0.0327 to –0.0025)
Pop½ (hr)  42.7 (26 to 119.5)  41.8 (22.3 to 341.4)  38 (23.7 to 95.7)  39.4 (21.2 to 280.2)
p-Value  0.002  0.026  0.001  0.023
0–4.5 hr            
No.  129  55  NA  NA
Median  2.6  2.7     
Fasting time betad (95% CI)  –0.0017 (–0.1467 to 0.1434)  –0.0101 (–0.2578 to 0.2375)     
Pop½ (hr)  418.3 (4.7 to –4.8)  68.4 (2.7 to –2.9)     
p-Value  0.98  0.94     
4.5–8.5 hr            
No.  441  147  368  129
Median  2.3  2.1  2.3  2.0
Fasting time betad (95% CI)  –0.1671 (–0.2685 to –0.0657)   –0.0924 (–0.2455 to 0.0607)   –0.1815 (–0.2924 to –0.0706)   –0.0865 (–0.2466 to 0.0737)
Pop½ (hr)  4.1 (2.6 to 10.6)  7.5 (2.8 to –11.4)  3.8 (2.4 to 9.8)  8.0 (2.8 to –9.4)
p-Value  0.0013  0.24  0.0014  0.29
8.5–24 hr            
No.  899  347  651  281
Median  2.4  2.3  2.4  2.3
Fasting time betad (95% CI)  –0.0184 (–0.0398 to 0.0031)   –0.0220 (–0.0523 to 0.0083)   –0.0256 (–0.0493 to –0.002)   –0.0188 (–0.0515 to 0.0138)
Pop½ (hr)  37.7 (17.4 to –225.4)  31.5 (13.2 to –83)  27.0 (14.1 to 352)  36.8 (13.5 to –50.1)
p-Value  0.093  0.16  0.034  0.26
NA, not applicable. 
aSample calculation: 0–24 hr fasting interval for all participants. The adjusted regression gave a fasting time beta (“slope”) of –0.0162 (95% CI, –0.0267 to –0.0058). The pop½ = 
–ln(2)/–0.0162 = 42.7 hrs. Lower bound of the 95% CI, –ln(2)/ –0.0267 = 26.0 hr; upper bound of the 95% CI, –ln(2)/ –0.0058 = 119.5 hr. As slope goes to zero, pop½ goes to infinity (i.e., BPA 
level is constant). A positive slope (increasing BPA with time) translates to “doubling time” and a negative pop½. Minor inconsistencies between slopes and population-based half-lives 
are attributable to rounding. bExcludes participants who reported consuming coffee/tea with cream/sugar, alcohol, gum, mints, lozenges, cough drops, antacids, laxatives, antidiarrhe-
als, or dietary supplements after “fasting” began (n = 48) or those who consumed diet soft drinks, coffee, or tea the previous day, and were therefore at higher risk of consuming these 
items during “fasting” (n = 920). Some subjects are in both groups. cExcludes participants with glucose ≥ 100 mg/dL if fasting time ≥ 4.5 hr. dFasting time beta coefficient (estimate) in the 
adjusted linear regressions; units are nanograms per milliliter per hour (natural log). BPA population-based half-life in NHANES
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sampling procedures and geographic coverage 
are superior. 
We do not suspect substantive BPA con-
tamination or measurement error, because CDC 
methods include a substantial quality control com-
ponent (CDC 2007b). NHANES 2003–2004 
procedures did not include the use of field blanks 
(Calafat A, personal communication), but we 
believe contamination during collection was 
unlikely because a) 6.5% of samples were below 
the LOD, which argues against systematic error 
across the entire sample, and b) BPA extremes 
were associated with sex, race, age, and income, 
which argues against substantial random error.
Although we used pharmacokinetic con-
cepts to assess BPA elimination in the popu-
lation, continued non  food exposure could 
completely obscure rapid clearance kinetics. 
Therefore the pop½ values obtained here should 
not be taken as true elimination half-lives, but 
as a method of quantifying the fact that BPA is, 
unexpectedly, still present despite extended fast-
ing by many NHANES participants.
More precisely, the concept of a population-
based half-life may be useful because the decline 
in population levels after termination of an 
exposure should match, at least grossly, the rate 
predicted by current exposure and pharma-
cokinetic assumptions. Population-based half-
life could be inflated by measurement error in 
population data, and its variance by differences 
in exposure. Nevertheless, a large discordance 
between the measured population-based rate 
and the rate predicted by current assumptions 
may be a clue that the assumptions are either 
incomplete or incorrect. Although, in our study, 
we used this approach to examine a food-based 
exposure, it could also be applicable whenever a 
significant population exposure can be abruptly 
terminated, such as when a pesticide is banned.
Risk assessments for BPA have been based 
in part on evidence that food is the primary, 
and almost exclusive, exposure source, and that 
rapid and complete BPA elimination occurs after 
exposure (European Chemicals Bureau 2003; 
European Food Safety Authority 2006; NTP 
2008). The persistence of population BPA levels 
despite extended fasting appears to contradict 
this evidence. Research to resolve this contradic-
tion could include experimental pharmaco  kinetic 
studies of chronic BPA exposure, continued 
search for important non  food sources, and fur-
ther investigation of BPA in human adipose tis-
sue and its effects on adipokine production. If 
such studies confirm that either or both of the 
base assumptions are flawed, risk assessments for 
BPA will require reevaluation.
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